NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Mukherjee, Somnath ^a   Hurt, Christopher N ^b   Gwynne, Sarah ^c   Bateman, Andrew ^d   Gollins, Simon ^e   Radhakrishna, Ganesh ^f   Hawkins, Maria ^a   Canham, Jo ^b   Lewis, Wyn ^g   Grabsch, Heike I ^h   Sharma, Ricky A ^a   Wade, Wendy ^c   Maggs, Rhydian ⁱ   Tranter, Bethan ⁱ   Roberts, Ashley ⁱ   Sebag Montefiore, David ^j,l   Maughan, Timothy ^a   Griffiths, Gareth ^k   Crosby, Tom ⁱ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c South West Wales Cancer Centre ^*  (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e GLAN CLWYD HOSPITAL   (United Kingdom)

^f St James's Institute of Oncology   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VELINDRE CANCER CENTRE   (United Kingdom)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy; Neo adjuvant; Oesophageal; Oxaliplatin; Paclitaxel; Phase II; Radiotherapy

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE DISSECTION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT RESPONSE; UNITED KINGDOM; ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGEAL NEOPLASMS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; PREOPERATIVE CARE;

EID: 84924029500     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1062-y     Document Type: Article

References (24)

1. Oesophageal cancer statistics. http://info.cancerresearchuk.org/cancerstats/types/oesophagus/
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062-7.
3. Khan OA, Cruttenden-Wood D, Toh SK. Is an involved circumferential resection margin following oesphagectomy for cancer an important prognostic indicator? Interact Cardiovasc Thorac Surg. 2010;11(5):645-8.
4. Dexter SPL, Sue-Ling H, McMahon MJ, Quirke P, Mapstone N, Martin IG. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001;48(5):667-70.
5. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462-7.
6. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-84.
7. Gwynne S, Falk S, Gollins S, Wills L, Bateman A, Cummins S, et al. Oesophageal chemoradiotherapy in the UK-current practice and future directions. Clin Oncol. 2013;25(6):368-77.
8. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538-43.
9. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
10. Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009;27(2):193-200.
11. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20(12):2844-50.
12. Chiarion-Sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2009;63(6):1111-9.
13. Wahba HA, El-Hadaad HA, Abd-Ellatif EA. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Med Oncol. 2012;29(3):1693-8.
14. O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, et al. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 2007;13(2):119-24.
15. Thukral A, Metz J, Hwang WT, O'Dwyer P, Plastaras J, Both S, et al. Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. Dis Esophagus. 2011;24(5):330-6.
16. Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103(9):1349-55.
17. Conroy T, Galais M-P, Raoul J-L, Bouché O, Gourgou-Bourgade S, Douillard J-Y, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305-14.
18. Dunnett CW. Selection of the best treatment in comparison to a control with an application to a medical trial. In: Santer TJ, Tamhane AC, editors. Design of Experiments: Ranking and Selection. New York: Marcel Dekker; 1984. p. 47-66.
19. Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 2009;92(2):164-75.
20. Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, et al. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466.
21. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer H-J, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851-6.
22. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3 - Results of a pilot study. J Reprod Med. 2002;47(9):701-5.
23. Palser T, Cromwell D, Van der Meulen J, Hardwick RH, Riley S, Greenaway K. The National Oesophago-Gastric Cancer Audit. An audit of the care received by people with Oesophago-gastric Cancer in England and Wales. In: Third Annual Report 2010. London: Centre NI; 2010.
24. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14(7):627-37.